Ramanathan Parameswaran1,2, Aleksandr Voskoboinik1,3,4, Alexandra Gorelik2, Geoffrey Lee1,2, Peter M Kistler2,3,4, Prashanthan Sanders5, Jonathan M Kalman1,2. 1. Department of Cardiology, Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria, Australia. 2. Department of Medicine, University of Melbourne, Building 181, Grattan Street, Melbourne Victoria, Australia. 3. Department of Cardiology, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria, Australia. 4. Department of Cardiac Electrophysiology, Heart Centre, Alfred Hospital, 55 Commercial Rd, Melbourne, Victoria, Australia. 5. Centre for Heart Rhythm Disorders, Royal Adelaide Hospital Cardiology 4G751-769, The University of Adelaide, Port Road, South Australia, Australia.
Abstract
Aims: Rotor mapping and ablation have gained favour over the recent years as an emerging ablation strategy targeting drivers of atrial fibrillation (AF). Their efficacy, however, has been a topic of great debate with variable outcomes across centres. The aim of this study was to systematically review the recent medical literature to determine the medium-term outcomes of rotor ablation in patients with paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PeAF). Methods and results: A systematic search of the contemporary scientific literature (PubMed and EMBASE) was performed in August 2017. Only studies assessing arrhythmia-free survival from rotor ablation of AF were included. We used the random-effects model to assess the primary outcome of pooled medium-term single-procedure AF-free survival for both PAF and PeAF. Success rates from multiple procedures and complication rates were also examined. We included 11 observational studies (4 PAF and 10 PeAF) with a total of 556 patients (166 PAF and 390 PeAF). Pooled single-procedure freedom from AF was 37.8% [95% confidence interval 5.6-86.3%] at a mean follow-up period of 13.8 ± 1.8 months for PAF and 59.2% (95% CI 41.4-74.9%) at a mean follow-up period of 12.9 ± 6 months for PeAF. There was a marked heterogeneity between studies (I2 = 93.8% for PAF and 88.3% for PeAF). The mean complication rate of rotor ablation among the reported studies was 3.4%. Conclusion: The wide variability in success rate between different centres performing rotor ablations suggests that the optimal ablation strategy, particularly targeting rotors, is unclear. Results from randomized studies are necessary before this technique can be considered as an established clinical tool.
Aims: Rotor mapping and ablation have gained favour over the recent years as an emerging ablation strategy targeting drivers of atrial fibrillation (AF). Their efficacy, however, has been a topic of great debate with variable outcomes across centres. The aim of this study was to systematically review the recent medical literature to determine the medium-term outcomes of rotor ablation in patients with paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PeAF). Methods and results: A systematic search of the contemporary scientific literature (PubMed and EMBASE) was performed in August 2017. Only studies assessing arrhythmia-free survival from rotor ablation of AF were included. We used the random-effects model to assess the primary outcome of pooled medium-term single-procedure AF-free survival for both PAF and PeAF. Success rates from multiple procedures and complication rates were also examined. We included 11 observational studies (4 PAF and 10 PeAF) with a total of 556 patients (166 PAF and 390 PeAF). Pooled single-procedure freedom from AF was 37.8% [95% confidence interval 5.6-86.3%] at a mean follow-up period of 13.8 ± 1.8 months for PAF and 59.2% (95% CI 41.4-74.9%) at a mean follow-up period of 12.9 ± 6 months for PeAF. There was a marked heterogeneity between studies (I2 = 93.8% for PAF and 88.3% for PeAF). The mean complication rate of rotor ablation among the reported studies was 3.4%. Conclusion: The wide variability in success rate between different centres performing rotor ablations suggests that the optimal ablation strategy, particularly targeting rotors, is unclear. Results from randomized studies are necessary before this technique can be considered as an established clinical tool.
Authors: George Leef; Fatemah Shenasa; Neal K Bhatia; Albert J Rogers; William Sauer; John M Miller; Mark Swerdlow; Mallika Tamboli; Mahmood I Alhusseini; Erin Armenia; Tina Baykaner; Johannes Brachmann; Mintu P Turakhia; Felipe Atienza; Wouter-Jan Rappel; Paul J Wang; Sanjiv M Narayan Journal: Circ Arrhythm Electrophysiol Date: 2019-07-29
Authors: Roland R Tilz; Corinna Lenz; Philipp Sommer; Meyer-Saraei Roza; Anne E Sarver; Christopher G Williams; Christian Heeger; Gerhard Hindricks; Julia Vogler; Charlotte Eitel Journal: Europace Date: 2021-05-21 Impact factor: 5.214
Authors: João Mesquita; Natasha Maniar; Tina Baykaner; Albert J Rogers; Mark Swerdlow; Mahmood I Alhusseini; Fatemah Shenasa; Catarina Brizido; Daniel Matos; Pedro Freitas; Ana Rita Santos; Gustavo Rodrigues; Claudia Silva; Miguel Rodrigo; Yan Dong; Paul Clopton; António M Ferreira; Sanjiv M Narayan Journal: PLoS One Date: 2019-07-03 Impact factor: 3.240
Authors: Balvinder S Handa; Caroline H Roney; Charles Houston; Norman A Qureshi; Xinyang Li; David S Pitcher; Rasheda A Chowdhury; Phang Boon Lim; Emmanuel Dupont; Steven A Niederer; Chris D Cantwell; Nicholas S Peters; Fu Siong Ng Journal: Comput Biol Med Date: 2018-07-17 Impact factor: 4.589